Information  X 
Enter a valid email address

Angel Biotechnology (ABH)

  Print      Mail a friend

Friday 21 December, 2007

Angel Biotechnology

Manufacturing Contract

Angel Biotechnology Holdings Plc
21 December 2007



                                                             21 DECEMBER 2007





                        ANGEL BIOTECHNOLOGY HOLDINGS PLC

                           ('Angel' or 'the Company')



                   Angel announces GMP manufacturing contract



Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract
manufacturer, is pleased to announce a new manufacturing contract.  The client
and terms of the contract have not been disclosed.



Under the contract, Angel is to manufacture batches of stem cells in their MHRA
Licensed GMP Facility in Edinburgh which specialises in the production of cell
based therapies



Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc,
said: 'Angel is very pleased to have been chosen by this client to manufacture
stem cells in our GMP facilities.  As one of only two manufacturing sites listed
by the MHRA for the production of cellular therapies to GMP, in the UK we
believe this represents an endorsement of Angel's commitment to quality and
service.  We look forward to further collaborations with this client in the
future.'



For further information, please call:
Angel Biotechnology Holdings plc                       Tel: +44 (0) 131 445 6077
Gordon Sherriff - COO                                  Tel: +44 (0) 7951 057016
Grant Thornton Corporate Finance
Colin Aaronson                                         Tel+44 (0) 20 7383 5100


About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process
development services and cGMP manufacturing to support biotechnology and
pharmaceutical companies worldwide.  Angel's principal activity is the
manufacture and supply of materials for use in early stage drug development and
pre-clinical studies, along with drug product and CMC documentation for Phases
I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team with wide ranging experience in biopharmaceutical
manufacture, gained in companies such as Glaxo, Serologicals Inc. and PPL
Therapeutics.

Angel was admitted to trading on AIM in November 2005.

More information at www.angelbio.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                                                    

a d v e r t i s e m e n t